Journal article
Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients
SQ Wong, A Fellowes, K Doig, J Ellul, TJ Bosma, D Irwin, R Vedururu, AYC Tan, J Weiss, KS Chan, M Lucas, DM Thomas, A Dobrovic, JP Parisot, SB Fox
British Journal of Cancer | Published : 2015
DOI: 10.1038/bjc.2015.80
Open access
Abstract
Introduction:Recent discoveries in cancer research have revealed a plethora of clinically actionable mutations that provide therapeutic, prognostic and predictive benefit to patients. The feasibility of screening mutations as part of the routine clinical care of patients remains relatively unexplored as the demonstration of massively parallel sequencing (MPS) of tumours in the general population is required to assess its value towards the health-care system.Methods:Cancer 2015 study is a large-scale, prospective, multisite cohort of newly diagnosed cancer patients from Victoria, Australia with 1094 patients recruited. MPS was performed using the Illumina TruSeq Amplicon Cancer Panel.Results:..
View full abstractGrants
Funding Acknowledgements
We gratefully acknowledge the cooperation of the following Victorian institutions: The Andrew Love Cancer Centre; Geelong Hospital, Barwon Health; Warrnambool Hospital; Southwest Health; The Peter MacCallum Cancer Centre; Ludwig Institute for Cancer Research, Austin Health; Royal Melbourne Hospital, Melbourne Health; Centre for Health Economics, Monash University; Department of Epidemiology and Preventative Medicine, The Alfred Centre, Monash University; Cabrini Health; Department of Pathology, University of Melbourne and Monash Institute of Medical Research. We thank all the cancer patients who participated in the study. We also thank all participating pathology laboratories involved in this study. We thank Helen Farrugia from the VCR for providing VCR data for this study. The results shown here are in whole or part based on data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This study was supported by the Victorian Government through the Victorian Cancer Agency Translational Research Program, the National Collaborative Research Infrastructure Strategy (NCRIS) of the Australian Government and Therapeutic Innovation Australia. SQW is supported by the Melbourne Melanoma Project funded by the Victorian Cancer Agency Translational research program, established through the support of the Victor Smorgon Charitable Fund.